Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors
Breast Cancer · 2024
DOI: 10.1007/s12282-024-01618-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer, 2024. Verfasst von Juan I Ruiz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Services Research, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Unit 1444, Houston, TX, 77030, USA. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Breast Neoplasms, SEER Program, Antirheumatic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Susan G. Komen, NIAMS NIH HHS.
Abstract (Originalsprache)
BACKGROUND: There have been concerns about the use of tumor necrosis factor inhibitors (TNFi) for autoimmune disease in patients with recently diagnosed cancer. We assessed the survival of patients with rheumatoid arthritis (RA) and newly diagnosed early breast cancer (BC) treated with TNFi in the first two years after BC diagnosis. METHODS: We identified patients in two datasets: (1) Optum's de-identified Clinformatics® Data Mart Database (CDM), (2) Surveillance, Epidemiology, and End Results program (SEER) and Texas Cancer Registry (TCR) Medicare-linked cohort. We grouped patients according to whether they received TNFi, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) only, or no DMARDs within 2 years after BC. Outcomes were overall survival (OS) and BC-specific survival (BCSS). We conducted landmark analyses at years 1 and 2, with multivariable Cox regressions using propensity scores for adjustment. RESULTS: In the first year after BC, 165/970 (17.0%) and 201/1246 (16.1%) patients received TNFi in CDM and SEER/TCR-Medicare respectively. In the 1 year landmark, no significant differences in OS were observed between patients treated with TNFi and patients treated with csDMARDs only in CDM (hazard ratio [HR] = 0.77, 95% confidence interval [CI] 0.42-1.40) or SEER/TCR-Medicare (HR = 0.84, 95% CI 0.54-1.31). BCSS (SEER/TCR-Medicare) was better in patients receiving TNFi than in those receiving csDMARDs only (HR = 0.28, 95% CI 0.08-0.98). In CDM, glucocorticoid therapy had worse OS than those without glucocorticoids (HR = 2.18, 95% CI 1.13-4.18). This was also observed in SEER/TCR-Medicare (not statistically significant). Similar results were observed for the 2 year landmark. CONCLUSIONS: TNFi treatment during the first two years after early BC was not associated with worse survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Services Research, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Unit 1444, Houston, TX, 77030, USA.
- Department of Management, Policy and Community Health, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Health Services Research, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Unit 1444, Houston, TX, 77030, USA. msalmazor@mdanderson.org.
Förderung
- NCI NIH HHS
- Susan G. Komen
- NIAMS NIH HHS
- NIH/National Cancer Institute through MD Anderson's Cancer Center Support Grant
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- NIH/National Cancer Institute through MD Anderson’s Cancer Center Support Grant
Zitieren
APA
Ruiz, J. I., Lei, X., Chi-Fang, W., Giordano, S. H., Zhao, H., Rajan, S. S., Lin, H., & Suarez-Almazor, M. E. (2024). Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors. Breast Cancer. https://doi.org/10.1007/s12282-024-01618-x
Vancouver
Ruiz JI, Lei X, Chi-Fang W, Giordano SH, Zhao H, Rajan SS, et al. Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors. Breast Cancer. 2024. doi:10.1007/s12282-024-01618-x
BibTeX
@article{Ruiz2024,
author = {Ruiz, Juan I and Lei, Xiudong and Chi-Fang, Wu and Giordano, Sharon H and Zhao, Hui and Rajan, Suja S and Lin, Heather and Suarez-Almazor, Maria E},
title = {Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors},
journal = {Breast Cancer},
year = {2024},
doi = {10.1007/s12282-024-01618-x}
}
EUVIMED